Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIA, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose, Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, and Immunogenicity Trial of AAB-001 in Patients With Mild to Moderate AD

NCT00112073 is registered in ClinicalTrials.gov with JANSSEN Alzheimer Immunotherapy Research & Development, LLC as lead sponsor.

NCT NCT00112073
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00112073 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIA, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose, Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, and Immunogenicity Trial of AAB-001 in Patients With Mild to Moderate AD
Lead sponsor
JANSSEN Alzheimer Immunotherapy Research & Development, LLC
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2005
Completion date
December 31, 2008
Enrollment
234 (actual)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer's disease